Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Moving along

RG wrote in his letter to the shareholders the following:

"The criteria we have outlined for M&A will target revenue-producing companies at, or near, operating profitability in niche, growth markets. I expect that we will use a combination of cash, equity, and less likely debt to accomplish these objectives.

My objective is to close our first M&A transaction before calendar year-end."

Share
New Message
Please login to post a reply